Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 
The feature you requested does not exist. However, we suggest the following feature:

Sumitomo Dainippon Pharma : announces Allogeneic iPS cell-derived Dopaminergic Neural Progenitor Cells Designated a “SAKIGAKE” Product by Japan’s Ministry of Health, Labour and Welfare

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/28/2017 | 07:03am CET

February 28, 2017 Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma announces Allogeneic iPS cell-derived Dopaminergic Neural Progenitor Cells Designated a "SAKIGAKE" Product by Japan's Ministry of Health, Labour and Welfare

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) announced today that allogeneic iPS cell-derived dopaminergic neural progenitor cells, for which the company address toward the practical use in collaboration with Professor Jun Takahashi of Center for iPS Cell Research and Application, Kyoto University, has been designated for "SAKIGAKE Designation System" product for regenerative medicine & cell therapy by the Ministry of Health, Labour and Welfare (MHLW) in Japan.

This cell product is dopamine neural progenitor cells derived from iPS cells.

The cells will be transplanted to Parkinson's disease patients to ameliorate neurological symptoms of Parkinson's disease by dopamine secreted and supplemented by the cells.

In collaboration with Professor Takahashi, Sumitomo Dainippon Pharma aims to acquire early approval of this cell product as regenerative medicine & cell therapy in Japan.

Reference Information SAKIGAKE Designation System:

The SAKIGAKE Designation System of the Ministry is designed to promote the development of innovative medical devices and regenerative medicine & cell therapy in Japan with a view to making them available as quickly as possible to patients in need. Designated products are given preferred procedural treatment in the consultation and review steps required for approval. The review period c

ould be as short as six months, thus reducing the overall time-to-market considerably.

Contact:

Public Relations/Investor Relations Sumitomo Dainippon Pharma Co., Ltd. TEL: +81-6-6203-1407 (Osaka);

+81-3-5159-3300 (Tokyo)

Dainippon Sumitomo Pharma Co. Ltd. published this content on 28 February 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 28 February 2017 06:03:15 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
07:03a SUMITOMO DAINIPPON PHARMA : announces Allogeneic iPS cell-derived Dopaminergic Neural Progenitor Cells Designated a “SAKIGAKE” Product by Japan’s Ministry of Health, Labour and Welfare
07:03a CAP GEMINI : Capgemini launches Applied Innovation Exchange in Singapore to serve Southeast Asia region
07:02a BANS HLDG : Senate confirms Wilbur Ross as Trump's Secretary of Commerce
07:02a TRACTOR SUPPLY : for municipal
07:02a ATHERTON RESOURCES : The Marketing Group Appoints New Chairman and Chief Financial Officer
07:02a ATHERTON RESOURCES : The Marketing Group Q4 & FY 2016 Year-End Report
07:02a HIAG IMMOBILIEN : – Annual Results 2016 Media Conference
07:02a EQS-ADHOC : Ein erfreuliches Geschäftsjahr für die Cham Paper Group
07:02a AKER ASA : Fourth-quarter and preliminary annual results 2016 - Net Asset Value of NOK 34.3 billion
07:02a ASETEK - Q4 2016 : Record Revenue and Profitability on Rising Demand for Liquid Cooling
Latest news
Advertisement
Hot News 
0.22%BHP Billiton Sees Oil Market Rebalancing in 2017
0.04%TSX posts lowest close in 3 weeks as gold shares fall
Most Read News
02/27 Facebook's virtual reality ambitions could be threatened by court order
02/27 TSX posts lowest close in 3 weeks as gold shares fall
02/27 Self-driving Nissan car takes to Europe's streets for first time
02/27 MORGAN STANLEY : gave some clients incorrect tax information
02/27 ALTERRA POWER : Feb 27, 2017 Alterra Power Announces HS Orka's 2016 Annual Results
Most recommended articles
02/27 Amazon, Netflix grab a share of Oscar glory
02/23DJVIVENDI : Full-Year Earnings Beat Estimates
12:58aDJAPPLE : Next iPhone Will Have a Curved Screen
12:46aDJCIMB BHD : Group 4Q Net Profit Rises 3.5% From a Year Earlier
12:46a SAMSUNG ELECTRONICS : South Korea prosecutors to charge Samsung Group chief and four other executives